Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

In this 13-week, multicenter trial, adults with insulin-treated type 2 diabetes were randomly ... Supported by Tandem Diabetes Care. Novo Nordisk provided the insulin aspart that was used in ...

Children and adults with type 1 diabetes had reductions in HbA1c ... Insulet, Medtronic, Novo Nordisk, Roche, Sanofi, Sinocare and Ypsomed; and receiving research support from Abbott, Embecta ...

An estimated 830 million people have diabetes, with type 2 being the most common. Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator ...